

primary studies - published RCT

Once-weekly azithromycin in cystic fibrosis with chronic *Pseudomonas aeruginosa* infection.

Code: PM18701270

Year: 2008 **Date:** 2008

Author: Steinkamp G

Study design (if review, criteria of inclusion for studies)

randomised double-blind, placebo-controlled trial

Participants

Thirty-eight patients (21 AZM/17 placebo) (mean age: 23.7 years; mean FEV(1): 62% of predicted) were recruited.

Interventions

patients received AZM or placebo 1 per week for 8 weeks (AZM dosage--20-29 kg: 500 mg, 30-39 kg: 750 mg, 40-49 kg: 1000 mg and > or = 50 kg: 1250 mg) after a course of intravenous antipseudomonal antibiotics.

Outcome measures

Pulmonary function tests, the serum markers LPS-binding protein (LBP), interleukin-8 (IL-8), CRP, *P. aeruginosa* alginate in sputum samples and quality of life scores were evaluated.

Main results

After treatment (mean dose of 21.2 mg/kg body weight once a week) pulmonary function declined in both groups compared to baseline (i.e. after cessation of i.v. antibiotics). The AZM group was significantly better for mean changes in serum CRP (AZM: +0.9 mg/l, placebo: +21.6 mg/l, $p=0.019$), lipopolysaccharide binding protein in serum, LBP (AZM: +0.9 microg/ml, placebo: +7.0 microg/ml, $p=0.015$), serum interleukin-8 (AZM: -3.1 pg/ml, placebo: +2.9 pg/ml, $p=0.001$) and alginate in sputum (AZM: +85 microg/ml, placebo: +353 microg/ml, $p=0.048$). Quality of life was significantly better after AZM and there was no increase in treatment-related adverse events.

Authors' conclusions

Once-weekly azithromycin ameliorated inflammatory reactions and improved quality of life. A decline of pulmonary function after cessation of i.v. antibiotics could not be prevented.

<http://dx.doi.org/10.1016/j.rmed.2008.03.009>

See also

Respir Med. 2008 Nov;102(11):1643-53. Epub 2008 Aug 12.

Keywords

Adult; Anti-Bacterial Agents; Azithromycin; Bacterial Infections; Drug Administration Schedule; Infection; pharmacological_intervention; *Pseudomonas aeruginosa*; *Pseudomonas*; Respiratory Tract Diseases; Respiratory Tract Infections; Intravenous; Macrolides; Anti-Inflammatory Agents; Anti-Inflammatory Agents - excl Steroids;